Diabetes Research and Clinical Practice
Volume 82, Issue 1 , Pages 93-97 , October 2008

Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type 2 diabetes mellitus

  • Kazunari Matsumoto

      Affiliations

    • Diabetes Center, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo, Nagasaki 857-1195, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 956 33 7151; fax: +81 956 34 4241.
    • ,
  • Naruhiro Fujita

      Affiliations

    • Diabetes Center, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo, Nagasaki 857-1195, Japan
    • ,
  • Kan Nakamura

      Affiliations

    • Diabetes Center, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo, Nagasaki 857-1195, Japan
    • ,
  • Takemasa Senoo

      Affiliations

    • Diabetes Center, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo, Nagasaki 857-1195, Japan
    • ,
  • Tan Tominaga

      Affiliations

    • Internal Medicine, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo, Nagasaki 857-1195, Japan
    • ,
  • Yukitaka Ueki

      Affiliations

    • Internal Medicine, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo, Nagasaki 857-1195, Japan

Received 22 August 2007 ,Revised 9 May 2008 ,Accepted 14 June 2008.

References 

  1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486–2497.
  2. Walldius G, Jungner I, Holme I, Aastveit A, Kolar W, Sreiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033
  3. Williams K, Sniderman A, Sattar N, D’Agostino R, Wagenknecht L, Haffner S. Comparison of the association of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003;108:2312–2316
  4. Corsetti J, Zareba W, Moss A, Sparks C. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis. 2004;177:367–373
  5. Howard B, Cowan L, Go O, Welty T, Robbins D, Lee E. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care. 1998;21:1258–1265
  6. Jiang R, Schulze M, Li T, Rifai N, Stampfer M, Rimm E, et al. Non-GDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 2004;27:1991–1997
  7. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  8. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194
  9. Matsumoto K, Sera Y, Abe Y, Ueki Y, Tominaga T, Miyake S. Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. Atherosclerosis. 2003;169:317–321
  10. Sung K, Hwang S. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis. 2005;180:161–169
  11. Alberti KGMM. Zimmet PZ for the WHO Consultation, Definition, Diagnosis and Classification of Diabetes Mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 1998;15:539–553
  12. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Correlation between carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism. 2002;51:244–247
  13. Matsumoto K, Sra Y, Ueki Y, Inukai G, Niiro E, Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet. Med. 2002;19:822–826
  14. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  15. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;22:818–822
  16. Hunt K, Resendez R, Williams K, Haffner S, Stern M. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio heart study. Circulation. 2004;110:1251–1257
  17. Howard G, O’Leary D, Zaccaro D, Haffner S, Rewers M, Hamman R, et al. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809–1817
  18. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-1: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J. Int. Med. 2004;255:188–205
  19. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais G, Lupien P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955–1961
  20. Garvey W, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453–462
  21. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet 344 (1994) 1383–1389.
  22. Shepherd J, Cobbe S, Ford I, Isles C, Lorimer A, MacFarlane P, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995;333:1301–1307
  23. Sacks F, Pfeffer M, Move L, Rouleau J, Rutherford J, Cole T, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996;335:1001–1009

PII: S0168-8227(08)00313-6

doi: 10.1016/j.diabres.2008.06.018

Diabetes Research and Clinical Practice
Volume 82, Issue 1 , Pages 93-97 , October 2008

Article Tools

* Image Usage & Resolution